BRPI0713150A8 - Regime em multidoses de vacinação de influenza poupador de adjuvante - Google Patents

Regime em multidoses de vacinação de influenza poupador de adjuvante

Info

Publication number
BRPI0713150A8
BRPI0713150A8 BRPI0713150A BRPI0713150A BRPI0713150A8 BR PI0713150 A8 BRPI0713150 A8 BR PI0713150A8 BR PI0713150 A BRPI0713150 A BR PI0713150A BR PI0713150 A BRPI0713150 A BR PI0713150A BR PI0713150 A8 BRPI0713150 A8 BR PI0713150A8
Authority
BR
Brazil
Prior art keywords
adjuvant
multidose
sparing
regime
influenza vaccination
Prior art date
Application number
BRPI0713150A
Other languages
English (en)
Portuguese (pt)
Inventor
Del Giudice Giuseppe
Manetti Riccardo
Original Assignee
Novartis Ag
Seqirus Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713150(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Seqirus Uk Ltd filed Critical Novartis Ag
Publication of BRPI0713150A2 publication Critical patent/BRPI0713150A2/pt
Publication of BRPI0713150A8 publication Critical patent/BRPI0713150A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BRPI0713150A 2006-06-15 2007-06-15 Regime em multidoses de vacinação de influenza poupador de adjuvante BRPI0713150A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81466506P 2006-06-15 2006-06-15
US60/814.665 2006-06-15
PCT/IB2007/002724 WO2007144772A2 (en) 2006-06-15 2007-06-15 Adjuvant-sparing multi-dose influenza vaccination regimen

Publications (2)

Publication Number Publication Date
BRPI0713150A2 BRPI0713150A2 (pt) 2012-03-27
BRPI0713150A8 true BRPI0713150A8 (pt) 2017-08-22

Family

ID=38832174

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713150A BRPI0713150A8 (pt) 2006-06-15 2007-06-15 Regime em multidoses de vacinação de influenza poupador de adjuvante

Country Status (17)

Country Link
US (3) US20090220545A1 (https=)
EP (1) EP2032163B1 (https=)
JP (2) JP5566687B2 (https=)
KR (1) KR20090016704A (https=)
CN (1) CN101500603A (https=)
AU (1) AU2007258874B2 (https=)
BR (1) BRPI0713150A8 (https=)
CA (1) CA2657989A1 (https=)
CY (1) CY1114315T1 (https=)
DK (1) DK2032163T3 (https=)
EA (1) EA017441B1 (https=)
ES (1) ES2401484T3 (https=)
PL (1) PL2032163T3 (https=)
PT (1) PT2032163E (https=)
SI (1) SI2032163T1 (https=)
WO (1) WO2007144772A2 (https=)
ZA (1) ZA200810582B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP5518041B2 (ja) * 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
KR101176305B1 (ko) * 2009-10-14 2012-08-23 웅진코웨이주식회사 붉나무 추출물을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
WO2011102873A1 (en) * 2010-02-21 2011-08-25 Innovative Bottles, Llc Biodegradable pharmacy container and safety cap
EP2525815B1 (en) * 2010-01-24 2015-02-25 Novartis AG Irradiated biodegradable polymer microparticles
US8852157B2 (en) 2010-02-21 2014-10-07 Innovative Bottles, Llc Disposable items made from bioplastic resins
PL2569007T3 (pl) * 2010-05-11 2016-04-29 Intervet Int Bv Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2016011343A1 (en) 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Her3 peptides and dendritic cell vaccines
WO2016068333A1 (ja) * 2014-10-30 2016-05-06 中外製薬株式会社 シリンジキャップを具備した、針付プレフィルドシリンジ製剤
US10406290B2 (en) 2015-02-03 2019-09-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled plastic syringe
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2019121513A1 (en) 2017-12-18 2019-06-27 Intervet International B.V. Swine influenza a virus vaccine
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001947A1 (en) 1988-08-25 1990-03-08 The Liposome Company, Inc. Affinity associated vaccine
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
DK1635863T3 (da) * 2003-06-17 2010-11-22 Mannkind Corp Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
JP5600375B2 (ja) * 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
AU2006310338A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adminstration routes for priming/boosting with influenza vaccines
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.

Also Published As

Publication number Publication date
CA2657989A1 (en) 2007-12-21
ZA200810582B (en) 2009-09-30
EA200970013A1 (ru) 2009-06-30
JP5566687B2 (ja) 2014-08-06
WO2007144772A3 (en) 2008-03-27
KR20090016704A (ko) 2009-02-17
US9901630B2 (en) 2018-02-27
US20090220545A1 (en) 2009-09-03
CY1114315T1 (el) 2016-08-31
US20120039934A1 (en) 2012-02-16
US20140370053A1 (en) 2014-12-18
EP2032163A2 (en) 2009-03-11
EP2032163B1 (en) 2013-01-23
CN101500603A (zh) 2009-08-05
DK2032163T3 (da) 2013-03-25
SI2032163T1 (sl) 2013-05-31
EA017441B1 (ru) 2012-12-28
US8808686B2 (en) 2014-08-19
AU2007258874B2 (en) 2013-11-14
HK1129205A1 (en) 2009-11-20
JP2009539965A (ja) 2009-11-19
JP5981951B2 (ja) 2016-08-31
WO2007144772A2 (en) 2007-12-21
JP2014098038A (ja) 2014-05-29
BRPI0713150A2 (pt) 2012-03-27
AU2007258874A1 (en) 2007-12-21
PL2032163T3 (pl) 2013-06-28
ES2401484T3 (es) 2013-04-22
PT2032163E (pt) 2013-04-11

Similar Documents

Publication Publication Date Title
BRPI0713150A8 (pt) Regime em multidoses de vacinação de influenza poupador de adjuvante
BRPI0510885A (pt) método de tratamento de lúpus e artigo industrializado
BRPI0517553A (pt) mecanismo de exposição de dose para um dispositivo de distribuição de fármaco
ECSP17077930A (es) Métodos y kits para tratar la depresión
CR11199A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
UY35362A (es) Compuestos terapéuticos
BRPI0716518B8 (pt) vacina de ipv e uso da mesma
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CO6390117A2 (es) Regimen de dosificación para un agonista de los receptores de s1p
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
CL2008003822A1 (es) Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer.
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CO6300949A2 (es) Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada
BR112013009789A2 (pt) inibidores do vírus da hepatite c
MX386380B (es) Forma de dosis de disolución rápida de vacuna oral que usa almidón.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112018068784A2 (pt) método para o tratamento de leucemia
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
AR054758A1 (es) Proceso de elaboracion de un epoxido a partir de una clorhidrina
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: SEQIRUS UK LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]